Clinical trial
Study of Bevacizumab Alone or Combined With Capecitabine and Oxaliplatin as…
NCT00335595 · Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Other · Completed
Key facts
| NCT number | NCT00335595 |
|---|---|
| Title | Study of Bevacizumab Alone or Combined With Capecitabine and Oxaliplatin as Support Therapy in Metastatic Colorectal Cancer Patients |
| Official title | Randomized, Multicenter, Phase III Study, to Evaluate the Efficacy and Safety of Bevacizumab Alone or Combined With Capecitabine and Oxaliplatin as Support Therapy After Initial Chemotherapy Treatment With Capecitabine, Oxaliplatin and Bevacizumab in Metastatic Colorectal Cancer Patients |
| Lead sponsor | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Other |
| Collaborators | Sanofi Industry Roche Pharma AG |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Drug |
| Interventions | XELOXA, XELOXA-A |
| Enrollment | 480 |
| Start date | Jul 1, 2006 |
| Primary completion | Jun 1, 2012 |
| Completion | Jun 1, 2012 |
| First posted | Jun 12, 2006 |
| Last update posted | Feb 20, 2013 |
| Countries | Spain |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: